Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.

Sang Min Lim, Kenneth D Westover, Scott B Ficarro, Rane A Harrison, Hwan Geun Choi, Michael E Pacold, Martin Carrasco, John Hunter, Nam Doo Kim, Ting Xie, Taebo Sim, Pasi A Jänne, Matthew Meyerson, Jarrod A Marto, John R Engen, Nathanael S Gray

Index: Angew. Chem. Int. Ed. Engl. 53(1) , 199-204, (2014)

Full Text: HTML

Abstract

We report the synthesis of a GDP analogue, SML-8-73-1, and a prodrug derivative, SML-10-70-1, which are selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras. Biochemical and biophysical measurements suggest that modification of K-Ras with SML-8-73-1 renders the protein in an inactive state. These first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling. Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.